Blood-Derived microRNA Signatures Associated with Hippocampal Structure and Atrophy Rate: Findings From the Rhineland Study

Why It Matters

The findings provide blood‑based molecular signatures that could enable earlier detection of neurodegenerative changes before clinical symptoms appear, offering new targets for biomarker development and therapeutic intervention in Alzheimer’s disease and related dementias.

Key Takeaways

• miR‑199a‑3p/199b‑3p, miR‑155‑5p, miR‑146a‑5p, miR‑505‑5p linked to larger left hippocampal volume
• miR‑361‑3p and miR‑4473 associated with slower left hippocampal atrophy
• miR‑381‑3p, miR‑370‑3p, miR‑543 (DLK1‑DIO3) reduce right hippocampal atrophy
• Five miRNAs jointly explain ~28% variance in left hippocampal atrophy
• Reverse MR suggests larger hippocampus lowers circulating miR‑6859‑5p levels

Pulse Analysis

MicroRNAs circulating in blood have emerged as promising, minimally invasive biomarkers for brain health, yet their relationship to specific neuroanatomical changes remains underexplored. The hippocampus, a critical hub for memory, is one of the earliest structures to exhibit volume loss in Alzheimer’s disease, making it a valuable target for early‑stage detection. By leveraging the large, population‑based Rhineland Study, investigators were able to pair high‑throughput miRNA sequencing with longitudinal MRI, providing a rare opportunity to map peripheral molecular signals onto precise structural trajectories.

The analysis uncovered two distinct miRNA signatures. A cross‑sectional panel—including miR‑199a‑3p/199b‑3p, miR‑155‑5p, miR‑146a‑5p and miR‑505‑5p—correlated with larger left hippocampal volume, suggesting these RNAs may reflect developmental or protective processes. In contrast, a longitudinal set comprising miR‑361‑3p, miR‑4473 and three DLK1‑DIO3 cluster miRNAs (miR‑381‑3p, miR‑370‑3p, miR‑543) was linked to slower hippocampal atrophy, collectively explaining almost 28 % of the variance in left‑side decline. Such effect sizes are notable for peripheral biomarkers and hint at underlying pathways—like TGF‑β signaling and mitochondrial autophagy—that could be modulated to preserve brain tissue.

While Mendelian randomization did not confirm a direct causal role for these miRNAs, the reverse‑direction finding that larger hippocampi suppress miR‑6859‑5p underscores a bidirectional interplay between brain structure and peripheral expression. Future work should validate these signatures in independent cohorts, integrate them with plasma protein and neuroimaging markers, and explore therapeutic delivery of protective miRNAs. If confirmed, blood‑based miRNA panels could become a cost‑effective front‑line screen, guiding early interventions before irreversible neurodegeneration sets in.